NASDAQ: AIMDAinos Inc Stock
$0.80+0.01 (+1.27%)
Updated Feb 3, 2023
AIMD Price
$0.80
Fair Value Price
$0.96
Market Cap
$16.01M
52 Week Low
$0.55
52 Week High
$18.00
P/E
-0.99x
P/B
0.44x
P/S
11.53x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.51M
Earnings
-$13.32M
Gross Margin
38.4%
Operating Margin
-528.96%
Profit Margin
-531.1%
Debt to Equity
0.07
Operating Cash Flow
-$3M
Beta
20.56
Next Earnings
Mar 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AIMD Overview
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AIMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIMD ($0.80) is undervalued by 16.49% relative to our estimate of its Fair Value price of $0.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AIMD ($0.80) is not significantly undervalued (16.49%) relative to our estimate of its Fair Value price of $0.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AIMD due diligence checks available for Premium users.
Be the first to know about important AIMD news, forecast changes, insider trades & much more!
AIMD News
Valuation
AIMD fair value
Fair Value of AIMD stock based on Discounted Cash Flow (DCF)
Price
$0.80
Fair Value
$0.96
Undervalued by
16.49%
AIMD ($0.80) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AIMD ($0.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AIMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.99x
Industry
10.7x
Market
15.09x
AIMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
5.11x
AIMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIMD's financial health
Profit margin
Revenue
$1.8M
Net Income
-$7.8M
Profit Margin
-445%
AIMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.1M
Liabilities
$2.7M
Debt to equity
0.07
AIMD's short-term assets ($3.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIMD's short-term assets ($3.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$786.6k
Investing
-$240.5k
Financing
$1.6M
AIMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIMD vs Biotech Stocks
Ainos Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.